Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients.

Abstract

BACKGROUND The efficacy of human recombinant erythropoietins (rHuEPOs) in the treatment of anemia with different etiologies is proven. Development of biosimilar rHuEPO products with lower cost and wider availability is important for the care of anemic patients. OBJECTIVE The aim of the present study was to determine the bioequivalence and safety of a… (More)
DOI: 10.1016/j.jsps.2015.02.007

Topics

  • Presentations referencing similar topics